Geron CEO Okarma Leaves as Company Turns to Dealmaking
This article is for subscribers only.
Geron Corp., the company conducting the first U.S.-authorized trial of human embryonic stem cells, said Chief Executive Officer Thomas B. Okarma has stepped aside as the company focuses on making deals with drugmakers.
Okarma will remain with Geron as a consultant while Chief Financial officer David L. Greenwood takes over as interim CEO, president and a member of the board of directors, the Menlo Park, California-based company said in a statement.